The effect of preoperative transarterial chemoembolization on the patient's outcome in resectable hepatocellular carcinoma
In‐Sook Kim(Frederick National Laboratory for Cancer Research), Dong Jin Suh(Daehang Hospital), Myoung Kuk Jang, Young‐Suk Lim(Asan Medical Center), Yung Sang Lee(The University of Texas at Dallas), Young Hwa Chung, Won Beom Choi, Kyu Bo Sung(Ulsan College), Han Chu Lee(Asan Medical Center), Sung Hoon Kim(Intelligent Image and Information System), Hyun‐Ki Yoon(SingHealth)
The Korean Journal of Internal Medicine
December 1, 2005
Cited by 7
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573